Startup Corvia Medical Inc. reported positive data from its first randomized, sham-controlled trial for a transcatheter, structural implant designed to treat some heart failure patients with no effective treatment options to relieve their symptoms. The Tewksbury, Mass.-based company already started a pivotal trial for the device, known as the Interatrial Shunt Device (IASD), during the second half of 2017.